Using topotecan and melphalan to treat retinoblastoma
Choice of Topotecan or Melphalan in Retinoblastoma Patients
This study is testing if giving the chemotherapy drugs topotecan and melphalan directly into the eye can effectively treat retinoblastoma while saving the eye from removal.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04799002 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness and potential complications of administering topotecan and melphalan through intraocular injection in patients diagnosed with retinoblastoma. It aims to provide a treatment option that spares the eyeball while addressing the cancer. The study is designed as a Phase 3 interventional trial, focusing on the outcomes of these chemotherapy agents in a specific patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with retinoblastoma who are receiving eyeball-sparing treatment.
Not a fit: Patients whose disease has progressed during follow-up may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive option for retinoblastoma patients, preserving their eyesight while effectively managing the disease.
How similar studies have performed: While this approach is being evaluated in this specific context, similar studies using chemotherapy agents for retinoblastoma have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed as retinoblastoma * receiving eyeball-sparing treatment Exclusion Criteria: * disease progression during follow-up
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Huashen Yang — Sun Yat-sen University
- Study coordinator: Huasheng Yang
- Email: yanghs64@126.com
- Phone: +00862087331539
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.